This SDS packet was issued with item:

078707683

The safety data sheets (SDS) in this packet apply to one or more components included in the items listed below. Items listed below may require one or more SDS. Please refer to invoice for specific item number(s).

078695525 078695541 078912799 078914044 078914045



Revision date: 02-Jan-2007 Version: 1.4 Page 1 of 7

IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING

Pfizer Inc
Pfizer Inc
Pfizer Pharmaceuticals Group
Ramsgate Road
235 East 42nd Street
Sandwich, Kent
New York, New York 10017
CT13 9NJ
1-212-573-2222
United Kingdom
+00 44 (0)1304 616161

Emergency telephone number: Emergency telephone number:

Material Name: Draxxin (Tulathromycin) solution for injection

Trade Name: Draxxin

Synonyms: Tulathromycin injectable solution

Chemical Family: Mixture

Intended Use: Pharmaceutical product used as antibiotic agent

2. COMPOSITION/INFORMATION ON INGREDIENTS

Hazardous

Ingredient	CAS Number	EU EINECS List	%
Tulathromycin	217500-96-4	Not listed	10
Monothioglycerol	96-27-5	202-495-0	*
Citric acid	77-92-9	201-069-1	*
Hydrogen chloride	7647-01-0	231-595-7	**
Sodium hydroxide	1310-73-2	215-185-5	**
Propylene glycol	57-55-6	200-338-0	*

Ingredient	CAS Number	EU EINECS List	%
Water	7732-18-5	231-791-2	*

Additional Information: * Proprietary

** to adjust pH

Ingredient(s) indicated as hazardous have been assessed under standards for workplace

safety.

3. HAZARDS IDENTIFICATION

Appearance: Clear, colorless to slightly yellow solution in multiple-dose vials

Signal Word: WARNING

Statement of Hazard: May cause eye irritation

May cause allergic skin reaction.

Additional Hazard Information:

Short Term: May cause eye and skin irritation (based on components). May cause allergic reaction (based

on animal data) . Individuals sensitive to this chemical or other materials in its chemical class may develop allergic reactions. Accidental ingestion may cause effects similar to those seen in

clinical use.

Material Name: Draxxin (Tulathromycin) solution for injection Page 2 of 7

Revision date: 02-Jan-2007 Version: 1.4

Known Clinical Effects: Ingestion of this material may cause effects similar to those generally seen in clinical use of

antibiotics including gastrointestinal irritation, vomiting, transient diarrhea, nausea, and

abdominal pain.

EU Indication of danger: Irritant

EU Hazard Symbols:



EU Risk Phrases:

R43 - May cause sensitization by skin contact.

Note: This document has been prepared in accordance with standards for workplace safety, which

require the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases.

Your needs may vary depending upon the potential for exposure in your workplace.

4. FIRST AID MEASURES

Eye Contact: Immediately flush eyes with water for at least 15 minutes. Get medical attention.

Skin Contact: Remove clothing and wash affected skin with soap and water. This material may not be

completely removed by conventional laundering. Consult professional laundry service. Do not

home launder. If irritation occurs or persists, get medical attention.

Ingestion: Get medical attention. Do not induce vomiting unless directed by medical personnel. Never

give anything by mouth to an unconscious person.

Inhalation: Remove to fresh air. If not breathing, give artificial respiration. Get medical attention.

5. FIRE FIGHTING MEASURES

Extinguishing Media: Use carbon dioxide, dry chemical, or water spray.

Hazardous Combustion Products: May emit toxic fumes of oxides of carbon and nitrogen.

Fire Fighting Procedures: During all fire fighting activities, wear appropriate protective equipment, including self-

contained breathing apparatus.

Fire / Explosion Hazards: Not applicable

6. ACCIDENTAL RELEASE MEASURES

Health and Safety Precautions: Personnel involved in clean-up should wear appropriate personal protective equipment (see

Section 8). Minimize exposure.

Measures for Cleaning / Collecting: Contain the source of spill if it is safe to do so. Collect spill with absorbent material. Clean spill

area thoroughly.

Measures for Environmental

Protections:

Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to

avoid environmental release.

Additional Consideration for Large

Spills:

Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.

Material Name: Draxxin (Tulathromycin) solution for injection Page 3 of 7
Revision date: 02-Jan-2007 Version: 1.4

7. HANDLING AND STORAGE

General Handling: Use appropriate ventilation. Avoid breathing dust, vapor or mist. Avoid contact with eyes, skin

and clothing.

Storage Conditions: Keep container tightly closed when not in use.

Storage Temperature: Store as directed by product packaging.

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Tulathromycin

Pfizer OEL TWA-8 Hr: 1 mg/m³, Sensitizer

Hydrogen chloride

ACGIH Ceiling Threshold Limit: = 2 ppm Ceiling
Australia PEAK = 5 ppm Peak
= 7.5 mg/m³ Peak

= 7.5 mg/m³ Peak

Sodium hydroxide

OSHA - Final PELS - TWAs: 2 mg/m³

ACGIH Ceiling Threshold Limit: = 2 mg/m³ Ceiling Australia PEAK = 2 mg/m³ Peak

Propylene glycol

Australia TWA = 10 mg/m³ TWA = 150 ppm TWA

= 474 mg/m³ TWA

The exposure limit(s) listed for solid components are only relevant if dust or mist may be generated.

Analytical Method: Analytical method available for Tulathromycin. Contact Pfizer Inc for further information.

Engineering Controls: Engineering controls should be used as the primary means to control exposures. Local and

general ventilation should be used as necessary, when handling this material in bulk.

Personal Protective Equipment:

Hands: Wear two layers of disposable gloves.

Eyes: Safety glasses or goggles

Skin: Protective coveralls should be worn. The sleeves should either be taped or have gloves worn

over them to prevent material from contacting the skin.

Respiratory protection: If the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate

respirator with a protection factor sufficient to control exposures to below the OEL.

9. PHYSICAL AND CHEMICAL PROPERTIES:

Physical State: Solution in multiple-dose vials Color: Colorless to slightly yellow

Molecular Formula: Mixture Molecular Weight: Mixture

pH: 5.4

Material Name: Draxxin (Tulathromycin) solution for injection Page 4 of 7
Revision date: 02-Jan-2007
Version: 1.4

10. STABILITY AND REACTIVITY

Stability:StableConditions to Avoid:None knownIncompatible Materials:No data available

Hazardous Decomposition Products: No data available **Polymerization:** Will not occur

11. TOXICOLOGICAL INFORMATION

General Information: The information included in this section describes the potential hazards of the individual

ingredients.

Acute Toxicity: (Species, Route, End Point, Dose)

Citric acid

Rat Oral LD50 3000 mg/kg

Propylene glycol

Mouse Oral LD50 22,000 mg/kg Rat Oral LD50 20,000 mg/kg Rabbit Dermal LD50 20,800 mg/kg

Tulathromycin

Rat Oral LDmin. > 2000 mg/kg Rabbit Dermal LD50 > 2000 mg/kg

Hydrogen chloride

Rat Inhalation LC50 1H 3,124 ppm Mouse Inhalation LC50 1H 1,108 ppm Mouse Oral LD50 900 mg/kg

Sodium hydroxide

Mouse IP LD50 40 mg/kg

Acute Toxicity Comments: A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable

at the highest dose used in the test.

<u>Irritation / Sensitization: (Study Type, Species, Severity)</u>

Citric acid

Eye Irritation Rabbit Severe Skin Irritation Rabbit Mild

Propylene glycol

Skin Irritation Rabbit Mild Eye Irritation Rabbit Mild

Tulathromycin

Skin Irritation Rabbit Non-irritating Eye Irritation Rabbit Positive

Skin Sensitization - GPMT Guinea Pig Severe

Sodium hydroxide

Eye Irritation Rabbit Severe Skin Irritation Rabbit Severe

Page 5 of 7

Material Name: Draxxin (Tulathromycin) solution for injection

Revision date: 02-Jan-2007 Version: 1.4

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

Tulathromycin

1 Month(s) NOAEL Rat Oral 50 mg/kg/day Liver, Blood 3 Month(s) Oral 15 mg/kg/day NOAEL Rat I iver 1 Month(s) Dog Oral 15 mg/kg/day NOAEL Liver 3 Month(s) Dog Oral 5 mg/kg/day NOEL Liver

1 Year(s) Dog Oral 5 mg/kg/day NOAEL Liver, Male reproductive system

Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

Tulathromycin

2 Generation Reproductive Toxicity Rat Oral 50 mg/kg/day NOAEL Paternal toxicity 2 Generation Reproductive Toxicity Rat Oral 100 mg/kg/day NOAEL Neonatal toxicity, Fertility Embryo / Fetal Development Rat Oral 200 mg/kg/day NOAEL No effects at maximum dose Embryo / Fetal Development Rabbit Oral 50 mg/kg/day NOAEL No effects at maximum dose

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Tulathromycin

Bacterial Mutagenicity (Ames) Salmonella Negative

In Vitro Chromosome Aberration Human Lymphocytes Negative *In Vivo* Micronucleus Chromosome Aberration Rat Negative

In Vitro Chromosome Aberration Chinese Hamster Ovary (CHO) cells Negative In Vitro Mammalian Cell Mutagenicity Chinese Hamster Ovary (CHO) cells Negative

Carcinogen Status: None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

Hydrogen chloride

IARC: Group 3

12. ECOLOGICAL INFORMATION

Environmental Overview: Based on the concentration of the active ingredient in the formulation, No harmful effects to

aquatic organisms are expected.

Bioaccumulation and Toxicity: The active ingredient was not acutely toxic to aquatic organisms at its maximum solubility. See

aquatic toxicity data, below.

Aquatic Toxicity: (Species, Method, End Point, Duration, Result)

Tulathromycin

Daphnia Magna OECD EC50 1 hr Hours > 20 mg/L Mysid Shrimp OECD LC50 48 Hours > 20 mg/L > 20 mg/L Sheepshead Minnow OECD LC50 48 Hours Red Algae OECD IC50 168 Hours > 20 mg/L

Aquatic Toxicity Comments: A greater than (>) symbol indicates that acute ecotoxicity was not observed at the maximum

solubility. Since the substance is insoluble in aqueous solutions above this concentration, an

acute ecotoxicity value (i.e. LC/EC50) is not achievable.

Bacterial Inhibition: (Species, Method, End Point, Duration, Result)

Page 6 of 7

Material Name: Draxxin (Tulathromycin) solution for injection

Revision date: 02-Jan-2007 Version: 1.4

Tulathromycin

Polytox IC-50 24 Hours 19 mg/L

13. DISPOSAL CONSIDERATIONS

Disposal Procedures: Dispose of waste in accordance with all applicable laws and regulations.

14. TRANSPORT INFORMATION

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

15. REGULATORY INFORMATION

EU Symbol: Xi EU Indication of danger: Irritant

EU Risk Phrases:

R43 - May cause sensitization by skin contact.

EU Safety Phrases:

S24/25 - Avoid contact with eyes and skin.

S37 - Wear suitable gloves.

OSHA Label:

WARNING

May cause eye irritation

May cause allergic skin reaction.

Canada - WHMIS: Classifications

WHMIS hazard class:

Class D, Division 2, Subdivision B



Water

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

EU EINECS List

Present
231-791-2

Monothioglycerol

Inventory - United States TSCA - Sect. 8(b) Present
Australia (AICS): Present

Material Name: Draxxin (Tulathromycin) solution for injection

Revision date: 02-Jan-2007 Version: 1.4

EU EINECS List 202-495-0

Citric acid

Inventory - United States TSCA - Sect. 8(b) Present Australia (AICS): Present **EU EINECS List** 201-069-1

Hydrogen chloride

CERCLA/SARA 313 Emission reporting = 1.0 % de minimis concentration acid aerosols including mists,

= 500 lb TPQ

vapors, gas, fog, and other airborne forms of any particle size

gas only

= 5000 lb EPCRA RQ gas only

Page 7 of 7

CERCLA/SARA Hazardous Substances = 2270 kg final RQ and their Reportable Quantities: = 5000 lb final RQ

CERCLA/SARA - Section 302 Extremely Hazardous

TPQs

CERCLA/SARA - Section 302 Extremely Hazardous

Inventory - United States TSCA - Sect. 8(b)

Substances EPCRA RQs

Australia (AICS): Present Standard for the Uniform Scheduling Schedule 5 for Drugs and Poisons: Schedule 6 **EU EINECS List** 231-595-7

Sodium hydroxide

CERCLA/SARA Hazardous Substances = 1000 lb final RQ and their Reportable Quantities: = 454 kg final RQ

Inventory - United States TSCA - Sect. 8(b) Present Australia (AICS): Present Standard for the Uniform Scheduling Schedule 5 Schedule 6

for Drugs and Poisons: **EU EINECS List** 215-185-5

Propylene glycol

Inventory - United States TSCA - Sect. 8(b) Present Australia (AICS): Present **EU EINECS List** 200-338-0

16. OTHER INFORMATION

Reasons for Revision: Updated Section 2 - Composition / Information on Ingredients. Updated Section 3 - Hazard

> Identification. Updated Section 5 - Fire Fighting Measures. Updated Section 6 - Accidental Release Measures. Updated Section 8 - Exposure Controls / Personal Protection. Updated

Section 13 - Disposal Considerations.

Prepared by: Toxicology and Hazard Communication

Pfizer Global Environment, Health, and Safety

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without a warranty of any kind, expressed or implied.

End of Safety Data Sheet



Revision date: 18-Sep-2013 Version: 3.1 Page 1 of 11

1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND THE COMPANY/UNDERTAKING

Product Identifier

Material Name: Draxxin (Tulathromycin) Solution for Injection

Trade Name: DRAXXIN

Synonyms: Tulathromycin injectable solution

Chemical Family: Mixture

Relevant Identified Uses of the Substance or Mixture and Uses Advised Against

Intended Use: Veterinary product used as antibiotic agent

Details of the Supplier of the Safety Data Sheet

Zoetis Inc. 100 Campus Drive, P.O. Box 651

Florham Park, New Jersey 07932 (USA)

Rocky Mountain Poison Control Center Phone: 1-866-531-8896

Product Support/Technical Services Phone: 1-800-366-5288

Zoetis Belgium S.A. Mercuriusstraat 20 1930 Zaventem

Belgium

Emergency telephone number:

CHEMTREC (24 hours): 1-800-424-9300

Contact E-Mail: VMIPSrecords@zoetis.com

Emergency telephone number:

International CHEMTREC (24 hours): +1-703-527-3887

2. HAZARDS IDENTIFICATION

Appearance: Clear, colorless to slightly yellow solution in multiple-dose vials

Classification of the Substance or Mixture

GHS - Classification

Serious Eye Damage/Eye Irritation: Category 2A

Skin Sensitization: Category 1

EU Classification:

EU Indication of danger: Irritant

EU Symbol: Xi

EU Risk Phrases:

R43 - May cause sensitization by skin contact.

Label Elements

Signal Word: Warning

Hazard Statements: H319 - Causes serious eye irritation

H317 - May cause an allergic skin reaction

Material Name: Draxxin (Tulathromycin) Solution for Injection

Revision date: 18-Sep-2013 Version: 3.1

Precautionary Statements: P261 - Avoid breathing dust/fume/gas/mist/vapors/spray

P264 - Wash hands thoroughly after handling

P280 - Wear protective gloves/protective clothing/eye protection/face protection P272 - Contaminated work clothing should not be allowed out of the workplace

P305 + P351 + P338 - IF IN EYES: Rinse cautiously with water for several minutes. Remove

Page 2 of 11

contact lenses, if present and easy to do. Continue rinsing P337 + P313 - If eye irritation persists: Get medical advice/attention P302+ P352 - IF ON SKIN: Wash with plenty of soap and water

P333 + P313 - If skin irritation or rash occurs: Get medical advice/attention

P362 - Take off contaminated clothing and wash before reuse

P501 - Dispose of contents/container in accordance with all local and national regulations



Other Hazards

Short Term: Individuals sensitive to this chemical or other materials in its chemical class may develop

allergic reactions. In the event of accidental injection, an allergic reaction may occur. If an allergic reaction occurs, the worker should be removed to the nearest emergency room and the

appropriate therapy instituted.

Known Clinical Effects: Ingestion of this material may cause effects similar to those generally seen in clinical use of

antibiotics including gastrointestinal irritation, vomiting, transient diarrhea, nausea, and

abdominal pain.

Australian Hazard Classification

(NOHSC):

Hazardous Substance. Non-Dangerous Goods.

Note: This document has been prepared in accordance with standards for workplace safety, which

require the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases.

Your needs may vary depending upon the potential for exposure in your workplace.

3. COMPOSITION/INFORMATION ON INGREDIENTS

Hazardous

Ingredient	CAS Number	EU EINECS/ELINCS List	EU Classification	GHS Classification	%
Tulathromycin	217500-96-4	Not Listed	Xi;R36-R43	Eye Irrit. 2A (H319) Skin Sens. 1 (H317) Aquatic Acute 3 (H402) Aquatic Chronic 3 (H412)	10
Citric acid	77-92-9	201-069-1	Xi; R36	Not Listed	**
Propylene glycol	57-55-6	200-338-0	Not Listed	Not Listed	*
HYDROCHLORIC ACID	7647-01-0	231-595-7	T; R23 C; R35	Skin Corr.1B (H314) STOT SE 3 (H335)	**

Material Name: Draxxin (Tulathromycin) Solution for Injection

Revision date: 18-Sep-2013 Version: 3.1

Ingredient	CAS Number	EU EINECS/ELINCS List	EU Classification	GHS Classification	%
Monothioglycerol	96-27-5	202-495-0	Not Listed	Not Listed	*
Water	7732-18-5	231-791-2	Not Listed	Not Listed	*

Additional Information: ** to adjust pH

* Proprietary

Ingredient(s) indicated as hazardous have been assessed under standards for workplace

Page 3 of 11

safety.

For the full text of the R phrases and CLP/GHS abbreviations mentioned in this Section, see Section 16

4. FIRST AID MEASURES

Description of First Aid Measures

Eye Contact: Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention

immediately.

Skin Contact: Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek

medical attention.

Ingestion: Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not

induce vomiting unless directed by medical personnel. Seek medical attention immediately.

Inhalation: Remove to fresh air and keep patient at rest. Seek medical attention immediately.

Most Important Symptoms and Effects, Both Acute and Delayed

Symptoms and Effects of For information on potential signs and symptoms of exposure, See Section 2 - Hazards

Exposure: Identification and/or Section 11 - Toxicological Information.

Medical Conditions None known

Aggravated by Exposure:

Indication of the Immediate Medical Attention and Special Treatment Needed

Notes to Physician: None

5. FIRE-FIGHTING MEASURES

Extinguishing Media: Use carbon dioxide, dry chemical, or water spray.

Special Hazards Arising from the Substance or Mixture

Hazardous Combustion May emit toxic fumes of oxides of carbon and nitrogen.

Products:

Fire / Explosion Hazards: Fine particles (such as dust and mists) may fuel fires/explosions.

Advice for Fire-Fighters

During all fire fighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

6. ACCIDENTAL RELEASE MEASURES

Personal Precautions, Protective Equipment and Emergency Procedures

Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

Page 4 of 11

Material Name: Draxxin (Tulathromycin) Solution for Injection

Revision date: 18-Sep-2013 Version: 3.1

Environmental Precautions

Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

Methods and Material for Containment and Cleaning Up

Measures for Cleaning / Absorb spills with non-combustible absorbent material and transfer into a labeled container for

disposal. Clean spill area thoroughly. Collecting:

Non-essential personnel should be evacuated from affected area. Report emergency **Additional Consideration for**

situations immediately. Clean up operations should only be undertaken by trained personnel. Large Spills:

7. HANDLING AND STORAGE

Precautions for Safe Handling

Avoid accidental injection. Minimize generating airborne mists and vapors. Avoid breathing mist or aerosols. When handling, use appropriate personal protective equipment (see Section 8). Wash hands and any exposed skin after removal of PPE. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors. HEPA filtration systems or other equivalent controls. Refer to Section 12 - Ecological Information, for information on potential effects on the environment.

Conditions for Safe Storage, Including any Incompatibilities

Store as directed by product packaging. Storage Conditions:

Specific end use(s): No data available

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Refer to available public information for specific member state Occupational Exposure Limits.

Tulathromycin

Zoetis OEL TWA 8-hr 1mg/m³, Sensitizer

Propylene glycol

Australia TWA 150 ppm

> 474 mg/m³ 10 mg/m^3

Ireland OEL - TWAs

150 ppm

470 ma/m³

10 ma/m³ 7 mg/m^3

Latvia OEL - TWA Lithuania OEL - TWA 7 mg/m^3

HYDROCHLORIC ACID

ACGIH Ceiling Threshold Limit: 2 ppm

Australia PEAK 5 ppm

 7.5 mg/m^3 5 ppm

Austria OEL - MAKs 8 mg/m^3

mag 2 **Belgium OEL - TWA** 8 ma/m³

8.0 mg/m³ **Bulgaria OEL - TWA** 5 ppm

5 ppm Cyprus OEL - TWA 8 mg/m³

Page 5 of 11

Material Name: Draxxin (Tulathromycin) Solution for Injection

Revision date: 18-Sep-2013 Version: 3.1

8. EXPOSURE CONTROLS	/ PERSONAL PROTECTION
----------------------	-----------------------

Czech Republic OEL - TWA 8 mg/m³ **Estonia OEL - TWA** 5 ppm 8 mg/m³ 2 ppm Germany - TRGS 900 - TWAs 3 mg/m^3 Germany (DFG) - MAK 2 ppm 3.0 mg/m³ **Greece OEL - TWA** 5 ppm 7 mg/m^3 **Hungary OEL - TWA** 8 mg/m³ **Ireland OEL - TWAs** 5 ppm 8 mg/m³ 5 ppm Italy OEL - TWA 8 mg/m³ Japan - OELs - Ceilings 5 ppm 7.5 mg/m³ 5 ppm Latvia OEL - TWA 8 mg/m³ 5 ppm Lithuania OEL - TWA 8 mg/m³ **Luxembourg OEL - TWA** 5 ppm 8 mg/m^3 Malta OEL - TWA mag 2 8 mg/m^3 **Netherlands OEL - TWA** 8 mg/m³ 5 mg/m³ Vietnam O EL - TWAs Poland OEL - TWA 5 mg/m³ 5 ppm Romania OEL - TWA 8 mg/m³ Slovakia OEL - TWA 5 ppm 8.0 mg/m^3 Slovenia OEL - TWA 5 ppm 8 mg/m^3 5 ppm Spain OEL - TWA 7.6 mg/m³

Exposure Controls

Switzerland OEL -TWAs

Engineering Controls: Engineering controls should be used as the primary means to control exposures. General

2 ppm

 3.0 mg/m^3

room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne

contamination levels below the exposure limits listed above in this section.

Personal Protective Refer to applicable national standards and regulations in the selection and use of personal

Equipment: protective equipment (PPE).

Hands: Wear impervious gloves to prevent skin contact.

Wear safety glasses or goggles if eye contact is possible. Eves:

Wear impervious protective clothing to prevent skin contact - consider use of disposable Skin:

clothing where appropriate.

Respiratory protection: If the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate

respirator with a protection factor sufficient to control exposures to below the OEL.

Material Name: Draxxin (Tulathromycin) Solution for Injection

Revision date: 18-Sep-2013 Version: 3.1

9. PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solution in multiple-dose vials Color: Colorless to slightly yellow

Odor: No data available. Odor Threshold: No data available.

Molecular Formula: Mixture Molecular Weight: Mixture

Solvent Solubility: No data available Water Solubility: No data available

pH: 5.4

Melting/Freezing Point (°C):

Boiling Point (°C):

No data available.

No data available.

Partition Coefficient: (Method, pH, Endpoint, Value)

No data available **Tulathromycin**

Measured 7.0 Log P -1.41

Decomposition Temperature (°C): No data available.

Evaporation Rate (Gram/s):

Vapor Pressure (kPa):

Vapor Density (g/ml):

Relative Density:

Viscosity:

No data available
No data available
No data available
No data available

Flammablity:

Autoignition Temperature (Solid) (°C):

Flammability (Solids):

Flash Point (Liquid) (°C):

Upper Explosive Limits (Liquid) (% by Vol.):

Lower Explosive Limits (Liquid) (% by Vol.):

Polymerization:

No data available
No data available
Will not occur

10. STABILITY AND REACTIVITY

Reactivity: No data available

Chemical Stability: Stable under normal conditions of use.

Possibility of Hazardous Reactions

Oxidizing Properties: No data available

Conditions to Avoid: Fine particles (such as dust and mists) may fuel fires/explosions. **Incompatible Materials:** As a precautionary measure, keep away from strong oxidizers

Hazardous Decomposition No data available

Products:

11. TOXICOLOGICAL INFORMATION

Information on Toxicological Effects

General Information: Toxicological properties of the formulation have not been investigated. The information

included in this section describes the potential hazards of the individual ingredients.

Acute Toxicity: (Species, Route, End Point, Dose)

Tulathromycin

PZ00052

Rat Oral LDmin. > 2000 mg/kg

Page 6 of 11

Material Name: Draxxin (Tulathromycin) Solution for Injection

Revision date: 18-Sep-2013 Version: 3.1

11. TOXICOLOGICAL INFORMATION

Rabbit Dermal LD50 > 2000 mg/kg

Citric acid

Rat Oral LD50 3000 mg/kg

Propylene glycol

Mouse Oral LD50 22,000 mg/kg Rat Oral LD50 20,000 mg/kg Rabbit Dermal LD50 20,800 mg/kg

Acute Toxicity Comments:

A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable

Page 7 of 11

at the highest dose used in the test.

Irritation / Sensitization: (Study Type, Species, Severity)

Tulathromycin

Skin Irritation Rabbit Non-irritating Eye Irritation Rabbit Positive

Skin Sensitization - GPMT Guinea Pig Severe

Citric acid

Eye Irritation Rabbit Severe Skin Irritation Rabbit Mild

Propylene glycol

Skin Irritation Rabbit Mild Eye Irritation Rabbit Mild

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

Tulathromycin

1 Month(s) Rat Oral 50 mg/kg/day NOAEL Liver, Blood 3 Month(s) Oral 15 mg/kg/day **NOAEL** Liver Rat 1 Month(s) Oral 15 mg/kg/day NOAEL Dog Liver 3 Month(s) Dog Oral 5 mg/kg/day NOEL Liver

1 Year(s) Dog Oral 5 mg/kg/day NOAEL Liver, Male reproductive system

Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

Tulathromycin

2 Generation Reproductive Toxicity
 2 Generation Reproductive Toxicity
 Rat Oral 50 mg/kg/day
 NOAEL Paternal toxicity
 Poral 100 mg/kg/day
 NOAEL Neonatal toxicity, Fertility

Embryo / Fetal Development Rat Oral 200 mg/kg/day NOAEL No effects at maximum dose Embryo / Fetal Development Rabbit Oral 50 mg/kg/day NOAEL No effects at maximum dose

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Tulathromycin

Bacterial Mutagenicity (Ames) Salmonella Negative

In Vitro Chromosome Aberration Human Lymphocytes Negative

In Vivo Micronucleus Chromosome Aberration Rat Negative

In Vitro Chromosome Aberration Chinese Hamster Ovary (CHO) cells Negative

In Vitro Mammalian Cell Mutagenicity Chinese Hamster Ovary (CHO) cells Negative

Page 8 of 11

Material Name: Draxxin (Tulathromycin) Solution for Injection

Revision date: 18-Sep-2013 Version: 3.1

11. TOXICOLOGICAL INFORMATION

Carcinogen Status: None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

HYDROCHLORIC ACID

Group 3 (Not Classifiable) IARC:

12. ECOLOGICAL INFORMATION

Environmental Overview: Environmental properties of the formulation have not been investigated. The following

information is available for the individual ingredients.

Toxicity:

Aquatic Toxicity: (Species, Method, End Point, Duration, Result)

Tulathromycin

Daphnia magna (Water Flea) OECD EC50 48 Hours 64 mg/L 48 Hours Mysidopsis bahia (Mysid Shrimp) OECD 20 ma/L LC50 Cyprinodon variegatus (Sheepshead Minnow) OECD LC50 48 Hours 20 mg/L Oncorhynchus mykiss (Rainbow Trout) OECD LC50 96 Hours >982 mg/LSelenastrum capricornutum (Green Alga) OECD EC-50 72 Hours 70 ug/L

Aquatic Toxicity Comments: A greater than (>) symbol indicates that acute ecotoxicity was not observed at the maximum

solubility. Since the substance is insoluble in aqueous solutions above this concentration, an

acute ecotoxicity value (i.e. LC/EC50) is not achievable.

Bacterial Inhibition: (Inoculum, Method, End Point, Result)

Tulathromycin

Polytox IC-50 19 mg/L

Persistence and Degradability: No data available

Bio-accumulative Potential:

Tulathromycin

No data available

Measured 7.0

Mobility in Soil: No data available

13. DISPOSAL CONSIDERATIONS

Waste Treatment Methods: Dispose of waste in accordance with all applicable laws and regulations. Member State

specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental

releases. This may include destructive techniques for waste and wastewater.

Material Name: Draxxin (Tulathromycin) Solution for Injection

Revision date: 18-Sep-2013 Version: 3.1

14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

15. REGULATORY INFORMATION

Safety, Health and Environmental Regulations/Legislation Specific for the Substance or Mixture

Canada - WHMIS: Classifications WHMIS hazard class:

Class D, Division 2, Subdivision B



Tulathromycin

CERCLA/SARA 313 Emission reporting

California Proposition 65

EU EINECS/ELINCS List

Not Listed

Not Listed

Monothioglycerol

CERCLA/SARA 313 Emission reporting

California Proposition 65

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

Present

EU EINECS/ELINCS List

Not Listed

Not Listed

Present

202-495-0

Citric acid

CERCLA/SARA 313 Emission reporting

California Proposition 65

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

Present

EU EINECS/ELINCS List

Not Listed

Not

Propylene glycol

CERCLA/SARA 313 Emission reporting

California Proposition 65

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

Present

EU EINECS/ELINCS List

Not Listed

Not Listed

Present

200-338-0

Water

PZ00052

Page 9 of 11

Page 10 of 11

Material Name: Draxxin (Tulathromycin) Solution for Injection

Revision date: 18-Sep-2013 Version: 3.1

15. REGULATORY INFORMATION

CERCLA/SARA 313 Emission reporting

California Proposition 65

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

REACH - Annex IV - Exemptions from the

Present

Present

obligations of Register:

EU EINECS/ELINCS List 231-791-2

HYDROCHLORIC ACID

CERCLA/SARA 313 Emission reporting 1.0 %
CERCLA/SARA Hazardous Substances 5000 lb and their Reportable Quantities: 2270 kg
CERCLA/SARA - Section 302 Extremely Hazardous 500 lb

TPQs

CERCLA/SARA - Section 302 Extremely Hazardous 5000 lb

Substances EPCRA RQs

California Proposition 65
Inventory - United States TSCA - Sect. 8(b)
Australia (AICS):
Standard for the Uniform Scheduling
for Drugs and Poisons:
Schedule 5
EU EINECS/ELINCS List

Not Listed
Present
Schedule 5
Schedule 5
Schedule 6
231-595-7

16. OTHER INFORMATION

Text of R phrases and GHS Classification abbreviations mentioned in Section 3

Sensitization, skin-Cat.1; H317 - May cause an allergic skin reaction

Serious eve damage/eye irritation-Cat.2A; H319 - Causes serious eye irritation

Skin corrosion/irritation-Cat.1B; H314 - Causes severe skin burns and eye damage

Hazardous to the aquatic environment, acute toxicity-Cat.3; H402 - Harmful to aquatic life

Hazardous to the aquatic environment, chronic toxicity-Cat.3; H412 - Harmful to aquatic life with long lasting effects Specific target organ toxicity, single exposure; Respiratory tract irritation-Cat.3; H335 - May cause respiratory irritation

T - Toxic

C - Corrosive

Xi - Irritant

R23 - Toxic by inhalation.

R35 - Causes severe burns.

R36 - Irritating to eyes.

R43 - May cause sensitization by skin contact.

Data Sources: The data contained in this MSDS may have been gathered from confidential internal sources,

raw material suppliers, or from the published literature.

Reasons for Revision: Updated Section 1 - Identification of the Substance/Preparation and the Company/Undertaking.

Prepared by: Toxicology and Hazard Communication

Zoetis Global Risk Management

Page 11 of 11

Material Name: Draxxin (Tulathromycin) Solution for Injection

Revision date: 18-Sep-2013 Version: 3.1

Zoetis Inc. believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

End of Safety Data Sheet